Citations

Clear

4799 citation(s) found for "Ro, Jennifer".

Case Report: Clinical characteristics and outcomes in natural killer (NK)/T-cell lymphomas with cardiac involvement: a case series and literature review
Robinson, Guy, Tayon, Kevin, Mukhia, Rupashi, Parker, Joseph B., Yang, William, Jiang, Jennifer , Ray, Jordan C., Yang, Vivienne , Tun, Han, Heybati, Kiyan , Robinson, Guy , Tayon, Kevin , Mukhia, Rupashi

Mayo Clinic

Frontiers in Cardiovascular Medicine | August 20, 2026 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fcvm.2026.1794186 | PMID 42694383 Get It

Background Cardiac involvement by extranodal natural killer/T-cell lymphoma (ENKTL) and aggressive NK-cell leukaemia (ANKL) is exceedingly rare and presents with heterogeneous manifestations, often leading to diagnostic uncertainty and delay. We contribute three additional biopsy- or autopsy-proven cases and place them in the context of a literature review of previously reported cases classified according to the 5th edition of the World Health Organization (WHO) Classification of Hematolymphoid Tumors. Case series Three men (ages 58–72) presented with diverse cardiac manifestations. A 72-year-old with progressive dyspnoea and cardiogenic shock had cMRI findings interpreted as myocarditis on an infiltrative substrate; endomyocardial biopsy confirmed cardiac infiltration by ENKTL. Despite brentuximab vedotin (BV)-based therapy he died shortly thereafter. A 60-year-old with encephalopathy, biventricular dysfunction, and widespread nodal/multiorgan disease had nodal pathology consistent with EBV-negative ANKL according to the criteria of the 5th edition of the WHO Classification of Hematolymphoid Tumors; he declined chemotherapy and died within six days, with autopsy confirming multiorgan (including myocardial and bone marrow) infiltration. A 58-year-old with prior sinonasal ENKTL treated with four cycles of SMILE developed a new right atrial mass one month later; the mass was diagnosed by cMRI/PET-CT concordance and an extracardiac (EBUS-lung) tissue confirmation of the same recurrence. BV followed by gemcitabine/oxaliplatin failed to control progression and he died approximately one month after cardiac spread. Across cases, CD56 was positive in all, EBER in two, and CD30 was expressed variably. Conclusions Cardiac ENKTL/ANKL is a rapidly fatal entity with protean features. Multimodal imaging aids early recognition and tissue targeting, but definitive diagnosis rests on tissue confirmation. L-asparaginase-based chemotherapy remains the treatment backbone; CD30- and PD-L1-guided agents such as BV, PD-1 blockade, and daratumumab may offer transient control after biomarker-guided selection but lack randomized data in cardiac disease. Across the reported experience, survival after cardiac involvement was uniformly short, typically days to a few months. Our three cases add to this literature by illustrating the diversity of cardiac presentations, the variable CD30 expression relevant to brentuximab vedotin use, and the contribution of multimodal imaging to diagnosis. Findings from our series and the pooled literature are descriptive rather than constituting a formal survival analysis, and underscore the need for earlier diagnosis and prospective investigation.
Acute Myeloid Leukemia Survivors Report Transplant-specific Burdens in Interviews Two Years after Receiving Allogeneic Hematopoietic Cell Transplantation During the Peak of the COVID-19 Pandemic: A Qualitative Study
McAndrew, Natalie S. , Patterson, S., Awoyinka, Iwalola, Costanzo, Erin S., Cole, Steve W. , Knight, Jennifer M., Patterson, Sam, Mohanraj, Lathika , Awoyinka, Iwalola , Knight, Jennifer M.

Mayo Clinic

INQUIRY: The Journal of Health Care Organization, Provision, and Financing | August 18, 2026 | Volume: 63 | Issue: No issue available | Pages: No page available

10.1177/00469580261478062 | PMID 42610368 Get It

Introduction Allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) entails prolonged recovery, serious complications, functional limitations, psychological distress, and extended isolation to prevent infection. During the peak of the COVID-19 pandemic, treatment disruptions, restricted caregiver access, and intensified isolation compounded these transplant-specific burdens. The longer-term influence of the pandemic experience on HCT recovery and survivorship remains poorly understood. Methods In this qualitative descriptive study, adults with AML who underwent allogeneic HCT from March through September 2020 participated in virtual semi-structured interviews from July 2022 through April 2023, approximately two years post-transplant. Participants were identified through the Center for International Blood and Marrow Transplant Research registry. Zoom or phone interviews were recorded, transcribed verbatim, and analyzed using inductive qualitative content analysis to describe survivorship experiences and opportunities to improve supportive care. Results A total of 25 AML survivors (ages 24-78, 56% male) were interviewed approximately two years post-transplant. Three themes were found: (1) Transplant is an arduous journey; (2) The COVID-19 pandemic shaped the transplant experience in complex and far-reaching ways; (3) Transplant demands sustained personal and relational investment throughout the transplant journey. Conclusions This study enhances our understanding of the stressors associated with transplantation during periods of heightened adversity, while also identifying opportunities to strengthen healthcare systems and supportive care services for this population. Situating these experiences within the context of a global health emergency offers a rare lens into how external stressors can exacerbate the already demanding nature of HCT survivorship. By understanding survivors’ experiences, healthcare systems can better anticipate and address the evolving needs of transplant survivors.
Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement
Grewal, Udhayvir S., Ear, Po H., Sonbol, Mohamad Bassam , Bellizzi, Andrew M., Dillon, Joseph S., Chan, Jennifer A., Howe, James R., Strosberg, Jonathan, Singh, Simron, Halfdanarson, Thorvardur R., Sonbol, Mohamad B , Ear, Po Hien , Bellizzi, Andrew M. , Hofland, Johannes , Crona, Joakim , Chan, Jennifer A. , Howe, James R. , Strosberg, Jonathan , Singh, Simron , Hálfdánarson, Þorvarður R.

Mayo Clinic

Cancer | August 17, 2026 | Volume: 132 | Issue: 16 | Pages: No page available

10.1002/cncr.70586 | PMID 42606162 Get It

Abstract Incretin‐based therapies, including glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and dual incretin agonists, are increasingly used for the management of diabetes, obesity, and cardiometabolic disease. Although their systemic benefits are well established, uncertainty remains regarding their safety in patients with neuroendocrine neoplasms (NENs), a biologically heterogeneous group of tumors with diverse molecular profiles. Preclinical studies suggest that GLP‐1 receptor activation may promote tumor growth in select receptor‐expressing models, although receptor expression varies widely across NEN subtypes and is often absent in common tumors such as ileal neuroendocrine tumors. Population‐level and retrospective clinical data have not demonstrated a consistent increase in oncologic risk but are limited by methodological constraints. In this expert consensus statement, the authors synthesize current evidence and provide a practical framework for the use of incretin mimetics in patients with NENs. The authors emphasize individualized risk assessment, shared decision‐making, and multi‐disciplinary collaboration, balancing potential but unquantified oncologic risks against substantial cardiometabolic benefits. Until prospective data are available, careful patient selection, dose optimization, and close clinical and radiologic surveillance remain essential to guide safe and effective use of these agents in this population.
Clinical, Genetic, and Endocrine Features of Bardet‐Biedl Syndrome in a Pediatric and Adult Cohort
Hassan, Doha , Salama, Mostafa , Muthusamy, Kalpana , Haqq, Andrea M., Scruggs, Brittni A. , Lanpher, Brendan C. , Tan, Queenie K.‐G. , Cramer, Carl H. , Rabatin, Amy E. , Koball, Afton M. , Darr, Kahlen , Bratcher, Paul M., Lamothe, Kathleen, Tenley, Jennifer B., Kumar, Seema , Tan, Queenie K-G , Biggs, Bridget K , Rabatin, Amy E , Koball, Afton , Schimmenti, Lisa A , Kumar, Seema , Salama, Mostafa , Scruggs, Brittni A , Cramer, Carl H , Haqq, Andrea M. , Biggs, Bridget K. , Schimmenti, Lisa A.

Mayo Clinic

American Journal of Medical Genetics Part A | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajmg.a.70276 | PMID 42596080 Get It

ABSTRACT Bardet‐Biedl syndrome (BBS) is a rare autosomal recessive disorder characterized by clinical and genetic heterogeneity. Data on the prevalence of clinical manifestations and comorbidities in BBS, particularly in pediatric patients, are limited. This study aimed to assess the prevalence and various manifestations of endocrine and other clinical comorbidities among pediatric and adult patients with BBS. This retrospective chart review included pediatric and adult patients with BBS evaluated at an academic tertiary care center in the United States between 2000 and 2024. The study included 31 patients (7 children and 24 adults) with seven identified pathogenic variants associated with BBS. The most common genetic etiology was biallelic variants in BBS1 (36%). Obesity was diagnosed in 86% of children and 100% of adults. No children had diabetes or prediabetes, whereas 46% of adults were affected. Dyslipidemia was identified in 29% of children and 46% of adults. No thyroid abnormalities were identified in children, whereas 25% of adults were affected. Retinal dystrophy was present in 71% of children and 96% of adults. Polydactyly was observed in 100% of children and 75% of adults. Chronic kidney disease was present in 29% of children and 63% of adults. This study highlights the clinical heterogeneity and substantial multisystem burden of BBS across pediatric and adult patients. The greater prevalence of diabetes/prediabetes, dyslipidemia, thyroid abnormalities, chronic kidney disease, and visual impairment among adults suggests that these complications may emerge or progress over time. Early recognition, proactive longitudinal surveillance, and comprehensive multidisciplinary care are essential to optimize management across the lifespan.
Reproducibility and Robustness of Large Language Models for Mobility Functional Status Extraction
Liu, Xingyi , Garg, Muskan, Jeon, Eunji , Jia, Heling , Sohn, Sunghwan , Garg, Muskan , Sauver, Jennifer L. St. , Pagali, Sandeep R.

Mayo Clinic

2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1424-1426

10.1109/ichi69079.2026.00227 Get It

Quantifying the Uncertainty and Risk Contributions of Activities of Daily Living Features in Dementia Prediction
Bag, Souvik, Jeon, Eunji , Garg, Muskan, Vassilaki, Maria, Petersen, Ronald C., Sauver, Jennifer St., Sohn, Sunghwan , St Sauver, Jennifer, Garg, Muskan , Liu, Xingyi , Vassilaki, Maria , Petersen, Ronald C., Sauver, Jennifer L. St.

Mayo Clinic

2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 291-296

10.1109/ichi69079.2026.00046 | PMID 42602482 Get It

Concurrent Validity and Between-System Agreement of a Commercial Wearable Inertial Sensor System for Gait and Postural Sway Assessment in Progressive Supranuclear Palsy
Novotny, Ryan , You, Sungmin , Hogen, Cecilia A., Whitwell, Jennifer L. , Josephs, Keith A. , Kaufman, Kenton R. , Ali, Farwa , Novotny, Ryan E , You, Victor S , Josephs, Keith A , Kaufman, Kenton R , Ali, Farwa

Mayo Clinic

Sensors | August 12, 2026 | Volume: 26 | Issue: 16 | Pages: 5105

10.3390/s26165105 | PMID 42655415 Get It

Wearable inertial measurement units (IMUs) offer an accessible alternative to optical motion capture (MoCap) gait analysis, but their performance in Progressive Supranuclear Palsy (PSP) requires validation. We assessed the concurrent validity of IMU-derived versus MoCap-derived gait metrics and static postural sway in 30 patients with PSP using Bland–Altman analysis, Intraclass Correlation Coefficients (ICC), and Spearman rank correlations. Finally, we assessed equivalence using the Two one-sided tests (TOST) procedure. Multivariable linear regression was used to determine whether clinical severity, as measured by the PSP Rating Scale (PSPRS), independently predicted absolute IMU measurement error while controlling for patient age and gait velocity. IMUs demonstrated excellent between-system agreement for parameters such as cadence (100.76 ± 11.42 vs. 100.52 ± 11.59) and cycle time (1.21 ± 0.15 vs. 1.22 ± 0.15; ICC > 0.98), despite a systematic underestimation of gait velocity (p < 0.05). Agreement significantly diminished for micro-phases (e.g., single/double support times) and spatial asymmetry. Interestingly, the TOST procedure revealed that only sagittal and transverse trunk kinematics were equivalent between systems, with all other measures failing to find equivalency. For static sway, the IMU demonstrated strong rank-order correspondence for tracking relative postural instability (ρ = 0.82, p < 0.05). Multivariable analysis revealed that higher PSPRS scores are independently associated with greater between-system discrepancies in support phases and pelvic and trunk kinematics (p < 0.05), irrespective of reduced gait speed. These findings highlight the need to develop disease-specific algorithms, rather than relying on normative commercial models, to establish reliable digital biomarkers for monitoring progressive motor decline.
Structural Heterogeneity of TDP‐43 Fragments in Alzheimer's Disease and Primary Age‐Related Tauopathy by Artificial Intelligence (AI)–Based 3D Segmentation
Uruk, Gӧkhan , Gatto, Rodolfo G. , Hossain, Nadia , Whitwell, Jennifer L. , Reichard, R. Ross, Josephs, Keith A. , Uruk, Gokhan , Whitwell, Jennifer L , Reichard, R. Ross

Mayo Clinic

Neuropathology and Applied Neurobiology | August 11, 2026 | Volume: 52 | Issue: 4 | Pages: No page available

10.1111/nan.70096 | PMID 42576167 Get It

ABSTRACT TAR DNA‐binding protein 43 (TDP‐43) inclusions are defining pathological features of frontotemporal lobar degeneration (FTLD) but are also often observed in Alzheimer's disease ( AD ) and primary age‐related tauopathy (PART). TDP‐43 in AD is either associated with cognitive impairment or a protective‐life prolonging impact, and yet the localization, cellular and fragment characteristics of TDP‐43 need to be determined. We investigated the relationships between TDP‐43 volumetric inclusion burden in low likelihood AD (lAD) and definite PART by immunostaining against phosphorylated TDP‐43 (pTDP‐43), TDP‐43 C terminal (TDP‐C) and TDP‐43 N‐terminal (TDP‐N) fragments combined with 3D confocal imaging taken from eight regions: amygdala (basolateral [amygdala‐BL] and centromedial amygdala [amygdala‐CM]), the hippocampus (Cornu Ammonis [CA]‐1, CA2/3, CA4, dentate gyrus [DG] and subiculum [SUB]) and entorhinal cortex (ERC) and artificial intelligence (AI)–based segmentation via object recognition, reconstruction and quantification. We found amygdala‐CM in lAD and PART to have the overall greatest burden of pTDP‐43 whereas TDP‐N burden in amygdala‐BL of PART cases was greater than other TDP‐43 fragments. There was no difference in TDP‐43 burden in hippocampal subfields in PART. However, CA2/3 region showed greater pTDP‐43 burden while TDP‐N stood out in DG and SUB. Multiple comparisons among the groups revealed that TDP‐C was the only fragment showing differences among PART and lAD in CA2/3, DG and SUB regions. Overall, unbiased AI‐based volumetric burden analysis pipeline demonstrated unique fragment aggregation patterns in the neurodegenerative processes of PART and AD .
Artificial intelligence–based 3D segmentation of tangle‐associated TDP ‐43 in neurodegeneration
Uruk, Gӧkhan , Gatto, Rodolfo G. , Hossain, Nadia , Whitwell, Jennifer L. , Reichard, Robert R., Josephs, Keith A. , Uruk, Gokhan , Youseff, Hossam , Whitwell, Jennifer L , Hossain, Nadia , Whitwell, Jennifer , Josephs, Keith A , Youssef, Hossam , Reichard, R. Ross

Mayo Clinic

Brain Pathology | August 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bpa.70131 | PMID 42568211 Get It

Abstract TAR DNA‐binding protein 43 (TDP‐43) inclusions are often associated with hyperphosphorylated tau, thus neurofibrillary tangles as the hallmark of Alzheimer's disease (AD) and primary age‐related tauopathy (PART). TDP‐43 in AD is associated with cognitive impairment, and while staging is known, the localization, cellular and inclusion characteristics of TDP‐43 are yet to be elucidated. We investigate relationships between TDP‐43 inclusions and the tangle maturation continuum in AD, PART, and co‐pathologies by multiplex immunostaining combined with artificial intelligence (AI)–based segmentation via object recognition, reconstruction, and quantification. We performed anti‐phosphorylated TDP‐43 immunofluorescence with phosphorylated tau labeling different stages and modifications of tangles (AT8, pS396, TauC3, MN423, GT38) in three controls, three cases with PART and TDP‐43 (PART‐TDP), five cases with high likelihood AD and TDP‐43 (AD‐TDP), and four cases of high likelihood AD with TDP‐43 and Lewy Body disease (AD‐TDP‐LBD). Confocal imaging was taken from eight regions: amygdala (amygdala‐BL and amygdala‐CM) and hippocampus (Cornu Ammonis (CA)‐1, CA2/3, CA4, dentate gyrus (DG), subiculum (SUB)), and entorhinal cortex (ERC) and quantified with AI segmentation to identify 3D spatial relations, thus the maturity of neurofibrillary tangle associated TDP‐43 (TAT) inclusions. TATs, which were either identified by pTDP‐43 and AT8 or pTDP‐43 and pS396 double positivity, were also investigated by Thioflavin S (ThioS) histochemistry. We found pS396 labeled mature TATs predominated in PART and AD in every region. Basolateral and centromedial amygdala displayed overall greatest number of pre‐TATs and mature TATs. Mature TATs were homogenously distributed among hippocampal subfields whereas CA4 and DG had the greatest mature TAT composition. ERC revealed closer numbers of pre‐TATs and mature TATs yet mature TATs predominated all groups. Unbiased AI‐based object identification, reconstruction, and TAT maturation analysis pipeline in conjunction with TDP‐43, tau, and ThioS multiplex immunostaining demonstrated unique aggregation and maturation patterns, highlighting region‐specific dynamics in the neurodegenerative processes of PART and AD.